Conning Inc’s Novo Nordisk NVO Stock Holding History

Conning Inc’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,832	Closed	-$293K	–	359
2023 Q4	$293K	Hold	2,832	–	–	0.01%	283
2023 Q3	$258K	Hold	2,832	–	–	0.01%	289
2023 Q2	$229K	Sell	2,832 -1,240	-30%	-$101K	0.01%	327
2023 Q1	$324K	Hold	4,072	–	–	0.01%	281
2022 Q4	$276K	Hold	4,072	–	–	0.01%	318
2022 Q3	$203K	Sell	4,072 -2,508	-38%	-$134K	0.01%	349
2022 Q2	$367K	Sell	6,580 -1,230	-16%	-$68.3K	0.01%	281
2022 Q1	$434K	Hold	7,810	–	–	0.01%	279
2021 Q4	$437K	Sell	7,810 -12,620	-62%	-$684K	0.01%	282
2021 Q3	$981K	Buy	20,430 +12,084	+145%	+$584K	0.03%	194
2021 Q2	$350K	Hold	8,346	–	–	0.01%	350
2021 Q1	$281K	Hold	8,346	–	–	0.01%	389
2020 Q4	$291K	Hold	8,346	–	–	0.01%	388
2020 Q3	$290K	Hold	8,346	–	–	0.01%	365
2020 Q2	$273K	Sell	8,346 -834	-9%	-$26.6K	0.01%	365
2020 Q1	$276K	Hold	9,180	–	–	0.01%	332
2019 Q4	$266K	Buy	+9,180	New	+$254K	0.01%	414

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Conning Inc's NVO Position: Q1 2024 in Review

Conning Inc sold out of Novo Nordisk (NVO) in Q1 2024, closing a stake of 2,832 shares — an estimated $293K sold.

Conning Inc first reported a position in NVO in Q4 2019 and held it in 17 quarters. The position peaked at $981K in Q3 2021. 1,744 funds tracked by Wall St. Rank hold NVO as of Q1 2024.

Conning Inc reported no remaining Novo Nordisk position as of Q1 2024 after selling out during the quarter.
Conning Inc sold 2,832 Novo Nordisk shares in Q1 2024, an estimated $293K.
Conning Inc first reported a position in Novo Nordisk in Q4 2019 and held it in 17 quarters.
Conning Inc's Novo Nordisk position peaked at $981K in Q3 2021.
1,744 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2024.

Based on Conning Inc's 13F filing for Q1 2024, filed 26 Apr 2024.